Want to see HK:0673 full AI Analyst Report?
Top Page
China Health Group
(0673)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$0.25
▼(-17.33% Downside)
Action:Reiterated
Date:08/21/26
The score is driven primarily by weak financial performance: persistent losses, sharply negative operating/free cash flow, and past negative equity outweigh the 2026 revenue rebound. Technicals reinforce the risk with a clear downtrend and negative momentum, while valuation offers limited support due to negative earnings and no dividend yield provided.
Positive Factors
Revenue Rebound
The sharp 2026 revenue rebound shows that the company retains some ability to generate renewed top-line activity after a weaker period. If this recovery persists, it could improve operating scale and provide a foundation for restoring profitability over the next several quarters.
Negative Factors
Persistent Unprofitability
Persistent losses and extremely negative margins show that the current revenue base is not supporting a viable earnings model. Without a substantial improvement in operating economics, the company may continue eroding capital and have limited ability to fund growth internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2026 revenue rebound shows that the company retains some ability to generate renewed top-line activity after a weaker period. If this recovery persists, it could improve operating scale and provide a foundation for restoring profitability over the next several quarters.
Read all positive factors
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$360.66M
Dividend YieldN/A
Average Volume (3M)15.93K
Price to Earnings (P/E)―
Beta (1Y)-0.05
Revenue Growth5.52%
EPS Growth56.54%
CountryHK
Employees111
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,387,138,200
10 Day Avg. Volume2,680
30 Day Avg. Volume15,925
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.44
Price to Sales (P/S)12.24
P/FCF Ratio-5.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Health Group Business Overview & Revenue Model
Company Description
Serving as an investment holding company, China Health Group Limited engages in a diverse range of operations. Within the People's Republic of China, its core business involves the supply and maintenance of medical equipment and disposables, coupl...
China Health Group Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 41.09M | 38.94M | 59.93M | 76.41M | 107.03M |
| Gross Profit | 7.13M | 9.23M | 13.64M | 27.19M | 28.69M |
| EBITDA | -43.34M | -63.71M | -37.42M | -33.04M | -4.38M |
| Net Income | -47.93M | -67.79M | -40.19M | -42.05M | -12.21M |
Balance Sheet | |||||
| Total Assets | 157.56M | 147.35M | 192.32M | 221.19M | 225.96M |
| Cash, Cash Equivalents and Short-Term Investments | 21.95M | 1.05M | 4.01M | 11.48M | 8.54M |
| Total Debt | 4.59M | 6.50M | 5.66M | 6.04M | 18.47M |
| Total Liabilities | 96.71M | 147.25M | 132.56M | 127.23M | 140.82M |
| Stockholders Equity | 53.27M | -7.66M | 52.04M | 86.33M | 79.58M |
Cash Flow | |||||
| Free Cash Flow | -86.28M | -8.35M | -7.03M | -9.59M | 31.00M |
| Operating Cash Flow | -85.64M | -6.76M | -6.40M | -8.22M | 31.80M |
| Investing Cash Flow | -653.00K | -1.58M | -301.00K | -5.40M | -35.29M |
| Financing Cash Flow | 104.96M | 8.79M | -1.24M | 27.66M | 12.96M |
China Health Group Technical Analysis
Negative
0.30
Price Trends
0.29
Negative
0.36
Negative
0.48
Negative
Market Momentum
-0.01
Positive
29.96
Positive
7.69
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0673, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.29, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 29.96 is Positive, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0673.
China Health Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% | |
65 Neutral | HK$50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% | |
63 Neutral | HK$64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% | |
41 Neutral | HK$360.66M | -5.30 | -273.18% | ― | 5.52% | 56.54% | |
39 Underperform | HK$575.63M | -6.46 | -2.60% | 17.10% | -2.55% | -145.60% |
* Healthcare Sector Average
HK:0673
China Health Group
0.26
-0.26
-50.00%
HK:2607
Shanghai Pharmaceuticals Holding Co
11.11
0.04
0.41%
HK:1099
Sinopharm Group Co
16.19
-2.24
-12.16%
HK:1931
IVD Medical Holding Limited
0.36
-6.64
-94.92%
HK:2192
Medlive Technology Co., Ltd.
6.31
-3.81
-37.66%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.49
0.38
7.46%
China Health Group Corporate Events
China Health Group Revamps Board, Appoints New INED and CFO
Oct 20, 2026
China Health Group Limited has reshaped its senior governance structure with the resignation of independent non-executive director Ms. Yang Huimin, who has moved into the role of chief financial controller, signalling a realignment of financial ov...
China Health Group details board and committee structure
Oct 20, 2026
China Health Group Limited has announced the current composition of its board of directors, comprising three executive directors, two non-executive directors and three independent non-executive directors. The disclosure highlights the mix of leade...
China Health Group Wins Unanimous Shareholder Backing at AGM
Sep 22, 2026
China Health Group Limited reported that all resolutions at its annual general meeting held in Shenzhen on 22 September 2026 were approved unanimously by shareholders via poll voting. The company’s audited consolidated financial statements f...
China Health Group Calls AGM to Renew Board Mandates and Seek New Share-Issuance Authority
Aug 6, 2026
China Health Group Limited has called its annual general meeting for 22 September 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements for the year ended 31 March 2026 and consider the re-appointment of it...
China Health Group Updates Bermuda Registered Office Address
Jul 31, 2026
China Health Group Limited has announced a change to the address of its registered office in Bermuda, effective 3 August 2026, relocating the office to Richmond House, 12 Par-la-Ville Road, Hamilton HM 08. The company confirmed that Tricor Investo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.